R
Robert Orlowski
Researcher at Merck & Co.
Publications - 14
Citations - 708
Robert Orlowski is an academic researcher from Merck & Co.. The author has contributed to research in topics: Pembrolizumab & Lenvatinib. The author has an hindex of 8, co-authored 14 publications receiving 351 citations.
Papers
More filters
Journal ArticleDOI
Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer
Vicky Makker,Matthew H. Taylor,Carol Aghajanian,Ana Oaknin,James W. Mier,Allen Lee Cohn,Margarita Romeo,Raquel Bratos,Marcia S. Brose,Christopher DiSimone,Mark Messing,Daniel E. Stepan,Corina E. Dutcus,Jane Wu,Emmett V. Schmidt,Robert Orlowski,Pallavi Sachdev,Robert Shumaker,Antonio Casado Herraez +18 more
TL;DR: Lenvatinib plus pembrolizumab showed promising antitumor activity in patients with advanced endometrial carcinoma who have experienced disease progression after prior systemic therapy, regardless of tumor MSI status.
Journal ArticleDOI
Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma.
Philippe Armand,Scott J. Rodig,Vladimir Melnichenko,Catherine Thieblemont,Kamal Bouabdallah,Gayane Tumyan,Muhit Ozcan,Sergio Portino,Laura Fogliatto,Maria D Caballero,Jan Walewski,Zafer Gulbas,Vincent Ribrag,Beth Christian,Guilherme Fleury Perini,Gilles Salles,Jakub Svoboda,Jasmine Zain,Sanjay R. Patel,Pei-Hsuan Chen,Azra H. Ligon,Jing Ouyang,Donna Neuberg,Robert A. Redd,Arkendu Chatterjee,Arun Balakumaran,Robert Orlowski,Margaret A. Shipp,Pier Luigi Zinzani +28 more
TL;DR: Pembrolizumab is associated with high response rate, durable activity, and a manageable safety profile in patients with rrPMBCL and was significantly associated with progression-free survival.
Journal ArticleDOI
PD-L1 gene alterations identify a subset of diffuse large B-cell lymphoma harboring a T-cell-inflamed phenotype.
James Godfrey,Sravya Tumuluru,Riyue Bao,Michael J. Leukam,Girish Venkataraman,John Phillip,Carrie Fitzpatrick,James McElherne,Brendan W. MacNabb,Robert Orlowski,Sonali M. Smith,Justin Kline +11 more
TL;DR: Results indicate that PD-L1 alterations identify a unique biological subset of DLBCL in which an endogenous antilymphoma immune response has been activated, and that is associated with responsiveness to PD-1 blockade therapy.
Journal ArticleDOI
Pembrolizumab in relapsed or refractory Richter syndrome
Philippe Armand,Niels Murawski,Daniel Molin,Jasmine Zain,Barbara Eichhorst,Zafer Gulbas,Eliza A Hawkes,John M. Pagel,Tycel Phillips,Vincent Ribrag,Jakub Svoboda,Anastasios Stathis,Arkendu Chatterjee,Robert Orlowski,Patricia Marinello,Beth Christian +15 more
TL;DR: Allogeneic Stem Cell Transplantation Provides Durable Remission in Patients with Primary Mediastinal Large B Cell Lymphoma, and long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma.
Journal ArticleDOI
A multicenter, open-label, randomized, phase III study to compare the efficacy and safety of lenvatinib in combination with pembrolizumab versus treatment of physician's choice in patients with advanced endometrial cancer
Vicky Makker,Nicoletta Colombo,Antonio Casado Herraez,Alessandro D. Santin,Emeline Colomba,David Miller,Keiichi Fujiwara,Sandro Pignata,Sally Baron-Hay,Isabelle Ray-Coquard,Ronnie Shapira-Frommer,Kimio Ushijima,Jun Sakata,Kan Yonemori,Yong Man Kim,Eva Guerra,Ulus Ali Sanli,Mary McCormack,Jie Huang,Alan D. Smith,Stephen Michael Keefe,Lea Dutta,Robert Orlowski,Domenica Lorusso +23 more
TL;DR: The phase III study results of LEN + pembro vs treatment of physician's choice (TPC) following platinum-based therapy in pts with advanced endometrial cancer (aEC) showed lenvatinib (LEN) + pembrolizumab (pembro) has efficacy in patients (pts).